Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Abscess: later-stage trial registry
1 of 14 indexed Abscess trials are currently recruiting, with more weight in Phase 3-4.
Corpus placement: #1,230 of 28,707 conditions by registered trial count.
14 US clinical trials · 1 currently recruiting · #1,230 of 28,707 conditions by registered trial count
Abscess: 14 US clinical trials tracked, 1 recruiting.
Abscess is the subject of 14 registered US clinical trials on ClinicalTrials.gov, 1 of them currently open to new participants. 8 are in Phase 3-4 (later-stage) and 3 in Phase 1-2 (earlier-stage). The most active sponsor is Melinta Therapeutics, running 2 of these trials.
Enrollment posture brief
Registry condition abscess
OPEN 1 | RECR 7% | LATE 8 | EARLY 3 | RANK #1230 | SPON 2
Volume-matched condition peers
Nearest open-share peer: Stage III Pancreatic Cancer (7% recruiting · 14 trials)
Abscess lists 1 open slots (7% of 14 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Abscess on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Abscess is recruiting below its size-band peers.
1 of 14 indexed trials (7.1%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Abscess trials is spread across many organizations.
Melinta Therapeutics accounts for 2 of 14 trials (14.3%). 13 distinct sponsors appear on at least one study for this condition label.
-
Typical Abscess enrolment sits around 108 participants.
Median target enrolment is 108 among the 14 trials that report a genuine target (sentinel values excluded). 6 of those (42.9%) plan for fewer than 100 participants.
-
Abscess research is mostly interventional.
14 interventional and 0 observational studies make up this index (100% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
14 total, page 1 of 1
Ketamine as a Supplement to Local Anesthesia for Minor Procedures
Loyola University
NCT06284473
Decreasing Antibiotic Duration for Skin and Soft Tissue Infection Using Behavioral Economics in Primary Care
Nationwide Children's Hospital
NCT05226260
Oritavancin Versus IV Vancomycin for the Treatment of Patients With Acute Bacterial Skin and Skin Structure Infection
Melinta Therapeutics
NCT01252732
Oritavancin Versus IV Vancomycin for the Treatment of Participants With Acute Bacterial Skin and Skin Structure Infection (SOLO I)
Melinta Therapeutics
NCT01252719
Efficacy and Safety of Dalbavancin for the Treatment of Acute Bacterial Skin and Skin Structure Infections
Durata Therapeutics Inc., an affiliate of Allergan
NCT01339091
Evaluation of 3 Versus 10 Days of Antibiotics in Skin Abscesses After Surgical Drainage
Lucy Holmes, MD
NCT02024867
Phase 2 Trial of TD 6424 (Telavancin) Versus Standard Therapy for Complicated Gram Positive Skin and Skin Structure Infections (Gram Positive cSSSI)
Cumberland Pharmaceuticals
NCT00061633
Incision and Drainage Versus Needle Aspiration in Soft Tissue Abscesses
University of Massachusetts, Worcester
NCT01085929
Aquacel Versus Iodoform Gauze for Filling Abscess Cavity Following Incision and Drainage
Valleywise Health
NCT00984022
Intranasal Fentanyl as an Adjunct to Lidocaine Infiltration in Adults Undergoing Abscess Incision and Drainage
Montefiore Medical Center
NCT03872700
Adjunctive Nitrous Oxide During Emergency Department Propofol Sedation in Adults
Albert Einstein Healthcare Network
NCT02410707
Management of Skin and Soft Tissue Abscesses in Pediatric Patients After Incision and Drainage
Baylor College of Medicine
NCT00691600
Safety and Feasibility Study of Methylene Blue Photodynamic Therapy to Sterilize Deep Tissue Abscess Cavities
University of Rochester
NCT02240498
Efficacy of Intranasal Fentanyl at Reducing Pain During Abscess Incision and Drainage (I&D) in Children
Columbia University
NCT01549002
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 1 |
| Phase 2 | 2 |
| Phase 3 | 7 |
| Phase 4 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Abscess records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Abscess trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Abscess page
14 registered trials, 1 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 1 Abscess trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Melinta Therapeutics sponsors the most Abscess trials on record, review their full trial history before evaluating a specific study. See Melinta Therapeutics's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Abscess condition card totals 14 registered trials; most-linked intervention Placebo; top US site state New York. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.